82results about How to "Control blood sugar levels" patented technology

The invention discloses a medicinal composition for treating diabetes. The medicinal composition consists of astragalus, gardenia, Szechuan lovage rhizome, siberian solomonseal rhizome, finger citron, root of red-rooted salvia, cinnamomvine, swordlike atractylodes rhizome, white paeony root, perilla fruit, kudzuvine root, fragrant solomonseal rhizome, oyster shell, rehmannia root, Chinese angelica, common anemarrhena rhizome, honeysuckle flower, heartleaf houttuynia herb, fresh imperata root, Chinese caterpillar fungus, semen nelumbinis, siberian solomonseal rhizome, cornus fruit, prepared rehmannia root, villous amomum fruit, liquoric root, medlar, asparagus, black sesame, tuckahoe, cherokee rose fruit, cistanche deserticola, angelica dahurica, adenophora, dark plum fruit, complanate astragalus seed, cassia seed, mulberry leaf, fresh reed rhizome, mint, oriental waterplantain rhizome, wrinkled gianthyssop herb and parslane herb. The medicinal composition can control the blood sugar level of various patients who suffer from the diabetes and improve the clinical symptoms of diabetes complications effectively. Therefore the medicinal composition can be used for treating the diabetesand the diabetes complications such as diabetic gastroparesis, diabetic nephroma, diabetic foot, diabetic neuropathy, diabetic eye diseases and diabetic pruritus and the like.

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and/or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

The invention relates to the technical field of biology, and particularly, relates to a recombinant human GLP-1-Fc fusion protein and a preparation method and an application thereof. The invention provides the recombinant human GLP-1-Fc fusion protein, wherein the recombinant human GLP-1-Fc fusion protein comprises two structural function regions which are respectively a recombinant GLP-1 fragment and a human immunoglobulin Fc fragment, and the recombinant GLP-1 fragment has the amino acid sequence shown in SEQID No.1. The recombinant human GLP-1-Fc fusion protein provided by the invention has the homology with an original GLP-1 molecule reaching 97%, and still maintains excellent biological activity and zoology activity.

The invention relates to a chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function. The chitosan oligosaccharide composite powder comprises, by weight, 40 to 60 parts of oat beta-glucan, 5 to 20 parts of chitosan oligosaccharide, 5 to 20 parts of sealwort extract, 3 to 8 parts of mulberry leaf extract, 2 to 6 parts of balsam pear extract, 0.05 to 0.5 part of chromium-rich yeast and 10 to 20 parts of a filler. The invention has the following advantages: the chitosan oligosaccharide composite powder is a chitosan oligosaccharide compound prepared from chitosan oligosaccharide and oat beta-glucan, used as main effective components, and a plurality of traditional Chinese medicinal active components, used as adjuvant materials, through refining in virtue of ultrasonic emulsification and spray drying technologies; the chitosan oligosaccharide composite powder has the advantages of good dissolvability, good dispersibility and high absorption and availability; all the components of the chitosan oligosaccharide composite powder cooperate with each other to exert substantial effect on promotion of blood glucose metabolism and maintenance and adjustment of the functions of the pancreas islet; moreover, a variety of active components included in the chitosan oligosaccharide composite powder has obvious synergism in improving the sensitivity of insulin and stabilizing postprandial blood sugar.

The invention discloses a weighing analyzing apparatus, comprising a weighing device, a storage device, input/output (I/O) equipment, a component analysis module and a guide module, wherein, the weighing device is used for transmitting a measuring result to the component analysis module; the component analysis module is used for inquiring component information of an object from an object componenttable of the storage device according to an object identification input by the I/O equipment, and calculating the component content of the weighed object according to the measuring weight result; andthe guide module is used for determining a guidance suggestion according to the component content and a preset guide program, and sending the suggestion to the I/O equipment for output. The inventionfurther discloses a weighing analysis method. The invention can realize automatic weighing and calculating, and simply and accurately obtain the guidance suggestion related to object weight.

The invention discloses a generalized predictive control closed-loop insulin infusion system based on an adaptive reference curve strategy. The system comprises a blood glucose detection module, a controller, a program module and an insulin pump, the blood glucose detection module is used for acquiring the blood glucose of a user, and an output end of the blood glucose detection module is connected with an input end of the controller through signals. The insulin pump is used for infusing insulin into the user, and an input end of the insulin pump is connected with an output end of the controller through signals. The program module is executed by the controller, acquires the blood glucose of the user through the blood glucose detection module and adjusts the infusion rate of the insulin pump according to a CARIMA (controlled autoregressive integral moving average) model, a minimum variance control algorithm and the adaptive reference curve strategy. According to the generalized predictive control closed-loop insulin infusion system based on the adaptive reference curve strategy, adaptive reference curves can be generated according to blood glucose fluctuation of different patients,so that the infusion rate of the insulin pump can be flexibly controlled.

The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type I diabetes protein antigenic epitope polypeptide and an immunosuppressor, 3.) a mixture of a type I diabetes protein antigen, a type I diabetes protein antigenic epitope polypeptide, and an immunosuppressor; the type I diabetes protein antigen is at least one of insulin, glutamic acid decarboxylase, and islet amyloid polypeptide, and the immunosuppressor is at least one of dexamethasone, cyclosporine A, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, early prednisolone, anti-CD4 monoclonal antibody, and anti-CD3 monoclonal antibody.

The invention discloses an inulin low-fat yogurt pudding and a preparation method thereof, and belongs to the technical field of food processing. The inulin low-fat yogurt pudding is prepared from the following components by weight percent: 30-40% of yogurt base, 2-10% of inulin, 0.05-0.5% of a thickener, 0.001-5% of a sweetening agent and the balance of water, wherein the inulin is a soluble dietary fiber, can selectively promote growth of colon probiotics, and has the functions of reducing blood sugar concentration, maintaining lipid metabolism balance, improving the bioavailability of mineral elements, enhancing the immunity of the organism, and the like. The inulin low-fat yogurt pudding disclosed by the invention contains the inulin dietary fiber, is low in fat content, and smooth in mouthfeel, has the functions of improving the intestinal microenvironment, controlling blood fat and blood sugar levels, reducing the energy, promoting absorption of a mineral substance and synthesis of vitamins, and is especially suitable for middle aged and elderly people with diseases such as constipation, obesity, hypertension, hyperlipidemia and diabetes mellitus.

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

The invention provides an individualized intervention formula food for diabetes and a preparation system thereof. The individualized intervention formula food for the diabetes is prepared by the following steps: 1), determining diabetes-related gene polymorphism sites which are effective for nutrient intervention; 2), detecting mutation of individual ADIPOQ gene, SLC30A8 gene and IL-6 gene; 3), evaluating mutation risk of the detected genes; and 4), determining addition amounts of various ingredients in the individualized intervention formula food, and preparing a corresponding individualized intervention formula food by using a preparation unit of the individualized intervention formula food. The individualized intervention formula food for the diabetes provided by the invention is capable of effectively reducing blood glucose level of patients with the diabetes.

The invention discloses a preparing method for oral insulin transport system in layer-by-layer self-assembly structure comprising the steps of separating out insulin nano ball with electropositivity by salting out method under the condition of low pH, and successively packing the insulin nano ball using polygalacturonic acid (PGLA) with electronegativity and chitosan (CS) with electropositivity by layer-by-layer self-assembly method according to the electrical property and electrostatic force of materials. The oral insulin transport system in the invention is characterized by nature, low toxicity, natural metabolism and degradation and excellent biocompatibility, and has small partical size, strong small-intestine absorption rate, high drug loading ratio and excellent stability. The system can quickly and potently exert the hypoglycemic effect of insulin and also obviously and quickly control the blood glucose level in a long-term with the potential of diabetes treatment.

The invention provides application of umbilical cord mesenchymal stem cells in preparing medicine for treating hyperglycemia and diabetic nephropathy by combining a traditional Chinese medicine extract. In the application disclosed by the invention, the medicine for treating the hyperglycemia and the diabetic nephropathy is prepared by combining the umbilical cord mesenchymal stem cells having differentiation capacity and having the capacity of treating diabetes with the traditional Chinese medicine extract which is capable of reducing blood glucose and improving the state of kidney and has aninhibition effect on kidney diseases caused by the diabetes, so that the blood glucose can be effectively controlled, and the kidney function can be improved.